Skip to main content
main-content
Top

The RITAZAREM trial


RITAZAREM results published: Support for rituximab maintenance therapy in AAV


Sunday 10 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA

Presenter: Rona Smith, University of Cambridge, UK

RITAZAREM involves 170 patients with antineutrophil cytoplasmic antibody- associated vasculitis and relapsing disease who on achieving remission at 4 months were randomly assigned to maintenance treatment with rituximab or azathioprine. The follow-up was a minimum of 36 months with the primary outcome being the time to disease relapse.

Back to the ACR/ARP 2019 conference hub